Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 34 n° 271

Posts Tagged ‘patient’

Sunnybrook Health Sciences Centre and Evident Partner to Improve Patient Outcomes in Canada

Posted by fidest press agency su sabato, 28 dicembre 2019

Sunnybrook Health Sciences Centre and Evident, a member of the CPSI (NASDAQ: CPSI) family of companies and a leading provider of electronic health record (EHR) systems and services, today announced that Sunnybrook and CPSI have signed definitive agreements to create a first-of-its-kind, Canadian-made Hospital Information System (HIS) solution. This announcement follows the letter of intent signed by the parties this past May. The combination of Sunnycare, Sunnybrook’s clinical workflow solution, and the Evident EHR platform will deliver a cost-effective alternative for managing hospital information and improving patient outcomes.
Development of the new solution will take place in their newly created Canadian Healthcare Innovation Centre, located in Toronto. The Innovation Centre will be a place for the companies to come together to plan, build, test, and develop on an ongoing basis, as well as share best practices and leverage other future partner organization’s collective strengths to enhance the delivery of healthcare in Canada. “This partnership is a win-win for the companies, as well as the patients and their providers across Canada,” said Boyd Douglas, president and chief executive officer of CPSI. “Combining our deep experiences, leadership and talent is a great advantage, as we work toward our shared goal of bringing this unique and competitive offering to the Canadian market in 2020 and beyond.”

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Glympse Bio Presents Preclinical Data Supporting Its Technology’s Potential to Improve NASH Patient Management

Posted by fidest press agency su lunedì, 11 novembre 2019

Glympse Bio, Inc., a life science company developing a non-invasive technology to directly query disease activity inside the body, today announced the presentation of preclinical data in support of the Glympse Liver Test in enabling early identification of disease stage, monitoring of fibrosis progression and early detection of drug-induced liver protection in NASH with high diagnostic accuracy. The abstract, entitled “Glympse Liver Test for Noninvasive Monitoring of Combination Drug Therapy in a Rat Model of Nonalcoholic Steatohepatitis (NASH),” is being presented at The Liver Meeting® 2019, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), in Boston.
Glympse Bio is pioneering the development of disruptive, non-invasive technology to directly query disease activity inside the body. The Company’s proprietary synthetic biomarkers – biological sensors developed using breakthroughs in science, engineering, medicine and artificial intelligence – are perfectly tunable to any disease, and offer earlier measures of response to disease and treatment. By integrating real-time biological activity with sophisticated machine learning and artificial intelligence, Glympse Inside™ is a pan-disease product engine that aims to transform disease monitoring and treatment response. The company is based at the Lab Central incubator in Cambridge, MA. For more information, please visit

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Blockchain-based Checksome™ to Accelerate Credentialing and Advance Patient Safety

Posted by fidest press agency su martedì, 22 ottobre 2019

Applied Statistics & Management, Inc. (ASM) introduces Checksome™, a blockchain-based technology, that contains nearly two million primary source verifications that are encrypted and secured by the blockchain. This data is critical for reducing credentialing processing times, while also providing proactive notifications for licensure changes. Checksome™ is available to all MD-Staff customers free of charge. MD-Staff is a cloud-based, AI-enabled, and user-friendly credentialing software solution backed by 30 years of innovation.Traditionally, there is a lot of duplicated credentialing work because each individual organization is independently verifying each practitioner’s licenses and credentials. Additionally, as practitioners are onboarded with different organizations, they must continually provide the same information to each. Checksome™ aims to solve this problem by providing a single, secure data repository using blockchain technology. “Checksome™ allows our customers to accelerate credentialing times, while allowing them to more proactively monitor their medical staff,” said Nick Phan, Executive Vice President of ASM. “Blockchain technology provides the security and trust required, while also eliminating duplicate work.”

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

New Tool Under Development May Help Arthritis Patients

Posted by fidest press agency su lunedì, 22 ottobre 2018

Study findings presented at the largest rheumatology meeting in the U.S. signal that people with arthritis may soon have information on overall outcome on a medication from a measure that combines the range of possible benefits and the full spectrum of potential side effects at the individual patient level.This study, along with seven other poster presentations of studies conducted with CreakyJoints and the ArthritisPower research registry in partnership with major academic institutions, will be presented during the 2018 ACR/ARHP Annual Meeting in Chicago, IL, October 19-24, 2018.“Based on their goals, a patient might be more willing to risk certain adverse events they consider “mild” or “livable,” if it means they can achieve their treatment target. But, currently, there is no existing resource to help people with rheumatoid arthritis (RA) and their doctors weigh the potential desirability of one medication compared to many other treatment options,” said Liana Fraenkel, M.D., MPH, Professor of Medicine (Rheumatology) at Yale School of Medicine and Section Chief of Rheumatology, VA Connecticut Healthcare System. “Our study aimed to develop a tool that will help RA patients compare the real-world experience of taking different medications, which is essential for informed treatment decisions.” The Global Patient-Reported Outcome Measure (G-PROM) quantifies and compares the distribution of patients’ overall experiences on medications based on trajectory mapping. To inform the trajectory mapping, study authors surveyed participants with RA from the ArthritisPower research registry (n=195) who compared an adverse event (AE) as worse, better, or no better or worse than a referent AE. These data allowed for the construction of a rank ordering of “equivalence classes,” or groups of AEs judged by participants as having a comparable impact on quality of life.A subsequent survey of ArthritisPower participants with RA (n=426), with similar demographic characteristics, were asked to indicate their preference for pairs of outcomes, where each outcome include both a specified level of benefit [little or no improvement, some improvement, and major improvement] and an AE. This resulted in a hierarchy of global outcomes from most preferable to least.With further validation, study authors predict that G-PROM will enable randomized controlled trials to report the percentage of patients classified into each level; thus, providing patients and their rheumatologists with a much clearer understanding of the range and likelihood of the total effects of competing treatment options on their quality of life. “Development of a Rheumatoid Arthritis Global Outcome Measure to Enable Comparisons of Patient Experiences across Treatment Arms in Randomized Clinical Trials,” will be discussed in an oral presentation on Wednesday, October 24 at 9:00am Central.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

High Student Debt, Patient Dropout Rates Emerge as Top Trends in 2018 State of Rehab Therapy Report

Posted by fidest press agency su lunedì, 16 luglio 2018

WebPT, the market-leading software platform for outpatient rehab therapists, released its annual State of Rehab Therapy report detailing the findings from its recent industry-wide survey of nearly 7,000 PT, OT and SLP professionals — including providers, executives, billers, clinic administrators and students from a wide array of specialties, settings and geographic locations. According to the report, the biggest trends and challenges facing the rehab therapy industry today include high patient dropout rates, mounting student debt, gender pay gaps and a lack of focus on marketing and growth strategy among rehab therapy practice leaders.Organized into five sections (demographics, business and financials, challenges and opportunities, salary, and technology), the 2018 report provides data on job satisfaction, billing and reimbursements, revenue, practice size, patient volume, career outlooks, top challenges and technology preferences. Key findings include:Only 10 percent of rehab therapy patients complete their prescribed care plan.
More than half of students surveyed will have more than $70,000 in debt at graduation, and more than a third will owe more than $100,000.One in two rehab therapy executives isn’t sure how much their organization spends on marketing efforts.
“WebPT initiated this survey last year to gain a better understanding of how rehab therapy stacks up in terms of patient success and engagement, billing and revenue, salary, and use of technology — among other important data sets — and to see how those metrics compare across clinic size, setting and location,” said Dr. Heidi Jannenga, PT, DPT, ATC/L, president and co-founder of WebPT. “Last year’s results serve as an important benchmark, and our goal is to use these findings to track how the PT, OT and SLP professions are changing and progressing over time. We also hope this data serves as a wake-up call, as there are still many areas in which we, as therapy professionals, need to improve — especially with respect to better advocating for ourselves and our patients at the state and national levels as well as demonstrating the unique value we provide.”

Posted in Estero/world news, scuola/school | Contrassegnato da tag: , , | Leave a Comment »

AntiCancer’s Oral Methioninase Overcomes Gemcitabine Resistance in Patient-Like Mouse Models of Pancreatic Cancer

Posted by fidest press agency su martedì, 26 giugno 2018

Pancreatic cancer is lethal in about 95% of cases mostly due to failure of first-line therapy gemcitabine. AntiCancer Inc.’s oral methioninase (AC 00619), which is in late pre-clinical development as an anti-cancer as well as an anti-aging drug, has now been shown to overcome gemcitabine resistance in mouse models of human pancreatic cancer, including AntiCancer’s patient-derived orthotopic xenograft (PDOX®) mouse models. The new results are to be published in the upcoming issue of Cancer Letters.“Methioninase can change the paradigm of pancreatic cancer therapy,” said Robert M. Hoffman, Founder of AntiCancer. “Methioninase is active against all cancer types, since they all require excess methionine compared to normal tissue, as seen in the use of radioactive methionine in positron emission tomography (PET) imaging, which gives the strongest PET signal due to the hunger of cancers for methionine,” said Hoffman.With AntiCancer’s strong patent position on oral methioninase, a very big commercial potential is expected. AntiCancer’s Methuselah Pharmaceuticals subsidiary has been formed to develop oral methioninase as a therapeutic for cancer, diabetes, obesity, hyperhomocysteinemia, and to extend the normal healthy life span.AntiCancer is also developing engineered bacteria to target all cancer types and has the most patient-like mouse models of cancer, including its PDOX® models, as well as MetaMouse®; AngioMouse®; its histoculture drug response assay (HDRA®), which is an in vitro test for first-line chemotherapy; and hair-follicle-associated-pluripotent (HAP) stem cells for regenerative medicine. AntiCancer was founded in 1984 with world headquarters in San Diego and subsidiaries in Tokyo, Seoul, Beijing, and Nanjing.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

Patient immune response could potentially prevent heart failure

Posted by fidest press agency su martedì, 24 aprile 2018

Vienna, Austria. Patients’ own immune response has the potential to prevent the development and progression of heart failure, according to research presented today at Frontiers in CardioVascular Biology (FCVB) 2018, a European Society of Cardiology congress.1 The study found antibodies in the plasma and heart muscle of end-stage heart failure patients. “The role of the immune response in the development of heart failure is unknown,” said Patricia van den Hoogen, a PhD student at the University Medical Centre Utrecht / Netherlands Heart Institute in Utrecht, the Netherlands. “We investigated the immune response in patients with end-stage heart failure to see if this might be a new target for treatment.” This study looked at whether patients with end-stage heart failure show signs of inflammation. After a heart attack, inflammation, which is the body’s normal immune response to injury, clears dead cells and other resulting debris. Heart attacks damage the heart muscle and may eventually lead to heart failure, which is a progressive disease. For patients with end-stage heart failure, heart transplantation may be the only treatment option. The study included 20 patients with end-stage heart failure and three healthy controls. Heart failure was caused by ischaemic heart disease (heart attack) in ten patients and by dilated cardiomyopathy in ten patients. The researchers analysed heart tissue and plasma samples to see which antibodies and other immune cells were present. Next they tested the samples with different epitopes to see if they could find the targets of the antibodies.The investigators found increased levels of antibodies in the heart and plasma of end-stage heart failure patients compared to healthy controls .Interestingly, antibody levels were higher in patients with ischaemic heart failure compared to those with dilated heart failure. Levels of other types of immune cells, including T cells, B cells, and macrophages, were significantly higher in the heart tissue of heart failure patients compared to healthy controls. In the plasma, heart failure patients had different types of B cells than healthy controls. Specifically, heart failure patients had more plasma B cells, which produce antibodies, and fewer regulatory B cells, which are immunosuppressive.The epitope screening to identify antibody targets is ongoing. Based on their initial results, the researchers have selected 200 epitopes for follow-up studies. Ms van den Hoogen said: “We observed more inflammation in patients with end-stage heart failure than in healthy people. Heart failure patients had higher levels of antibodies, and more of the cells that produce antibodies. This suggests that the inflammatory response is activated and might play an important role in heart failure.” “These patients were in the final stage of heart failure,” she added. “In future studies we will investigate whether there is an inflammatory response in the early phase of heart failure, and whether the response becomes more pronounced as heart failure worsens.” She concluded: “We now know there is an inflammatory response in patients with end-stage heart failure. This paves the way for creating new therapies to prevent the development or progression of heart failure by targeting the immune response. If we identify the targets of the antibodies through our epitope screening, personalised treatments could be designed.”

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

6th Annual World Patient Safety, Science & Technology Summit Is SOLD OUT!

Posted by fidest press agency su sabato, 10 febbraio 2018

Joe KianiThanks to overwhelming demand to hear the latest advances in patient safety, registration for the 6th Annual World Patient Safety, Science and Technology Summit is now closed. In order to make sure that as many people as possible can attend, we have made the Summit available online via live streaming.The entire Patient Safety Movement Foundation team is committed to increasing awareness about the exciting and innovative patient safety developments emanating from the summit. There will be keynote addresses from leading political figures and patient safety experts, plenary sessions with healthcare luminaries, members of the press and patient advocates, as well as announcements from organizations who have made their own commitments to reach the Patient Safety Movement Foundation’s goal of ZERO preventable deaths by 2020.
More than 200,000 U.S. patients and three million worldwide die each year from preventable causes. The Patient Safety Movement Foundation (PSMF) was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare to reduce that number of preventable deaths to zero by 2020 (0X2020). Improving patient safety requires a collaborative effort from all stakeholders, including patients, healthcare providers, medical technology companies, government, employers, and private payers. The PSMF works with all stakeholders to address problems with actionable solutions. The Foundation also convenes the World Patient Safety, Science and Technology Summit bringing together some of the world’s best minds for thought-provoking discussions and new ideas that challenge the status quo. By presenting specific, high-impact solutions to meet patient safety challenges, called Actionable Patient Safety Solutions, encouraging medical technology companies to share the data their products are purchased for, and asking hospitals to make commitments to implement Actionable Patient Safety Solutions, the Patient Safety Movement Foundation is working toward zero preventable deaths by 2020. (photo: Joe Kiani)

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

CMR 2018 showcases advances in cardiovascular magnetic resonance improving patient care

Posted by fidest press agency su giovedì, 18 gennaio 2018

barcellonaBarcelona, Spain 31 January to 3 February CMR 2018 will showcase the latest advances in cardiovascular magnetic resonance (CMR) and how they are improving patient care and outcomes. CMR 2018 is a joint EuroCMR and SCMR meeting organised by the European Association of Cardiovascular Imaging (EACVI), a registered branch of the European Society of Cardiology, and the Society for Cardiovascular Magnetic Resonance (SCMR).It will be held 31 January to 3 February in Barcelona, Spain, at the Centre Convencions Internacional de Barcelona (CCIB). The scientific programme is available hereThe congress theme ‘improving clinical value by technical advances’ emphasises how new developments in CMR benefit patients. Higher quality images increase understanding of disease and enable better diagnosis and treatment, while faster scan times help reduce waiting lists and provide a better patient experience.CMR has a major role to play in the prevention of sudden cardiac death and will be debated at CMR 2018 by leaders in the fields of imaging and arrhythmias. Professor Josep Brugada, a leading clinical cardiologist and arrhythmia expert based in Barcelona, will give a keynote lecture on the latest developments in ventricular arrhythmias. Other distinguished speakers include ESC President Professor Jeroen Bax.Dr Jose Palomares, CMR 2018 abstract co-chairperson (representing EuroCMR), said: “International clinical and CMR specialists will provide the most up-to-date information in different disease areas. They will also reveal what is on the horizon in terms of furthering our understanding of what causes diseases and how to best diagnosis and treat them.”
Heart disease causes many deaths in women but the way it develops is different to men. In women, heart disease mainly affects the microvessels, making it more difficult to detect. “CMR is particularly well suited to helping us understand heart attacks in women and how to better manage them,” said Dr Allison Hays, CMR 2018 abstract co-chairperson (representing SCMR).Artificial intelligence is a hot topic and will be the focus of a session on deep learning/machine learning. Professor Daniel Rueckert, a leader in machine learning development in magnetic resonance, will join other specialists to discuss how these areas are revolutionising CMR by boosting productivity and expanding the limits of what can be measured. Novel methods will be presented along with technological advances in this rapidly developing field.CMR is increasingly being used to detect metabolic changes in the heart. Specialists will show how imaging detects fat build up in the heart, which can predict who will develop heart failure and arrhythmias and indicate the impact of medications and lifestyle changes.Around 1–2% of adults in developed countries have heart failure but treatments are available and some cases can even be prevented. Novel CMR techniques like T1 mapping are being used for the early detection of fibrosis in the heart to identify patients at risk for heart failure. A number original scientific abstracts will show the latest findings in this field.
Ischaemia imaging is another focus in the abstracts, which show the value of CMR in diagnosing and risk stratifying patients with suspected coronary artery disease in a standardised way. Clinical trial results will be presented showing how CMR can be used cost effectively to improve patient outcomes. A workshop will be held in conjunction with the International Society for Magnetic Resonance in Medicine (ISMRM).Dr Palomares said: “Scientific information is growing exponentially. CMR 2018 brings together leading clinicians and imagers from across the globe to highlight the key developments in cardiovascular magnetic resonance and where the boundaries of science and medicine are being pushed.”Dr Hays said: “The important technical advances and large scale clinical trials in CMR will be presented, making CMR 2018 an event not to be missed. Patient outcomes are a big focus of the conference – we are not just taking pictures of the heart, we are applying it in a clinically meaningful way to improve healthcare.”

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

GI Dynamics Welcomes New Members to Its Scientific Advisory Board

Posted by fidest press agency su giovedì, 17 agosto 2017

london-centralLondon. GI Dynamics® Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, welcomed new members to the GI Dynamics Scientific Advisory Board (SAB), bringing together distinguished physicians and scientists specializing in endocrinology, gastroenterology and bariatric/metabolic surgery. Gerald Holtmann, MD, and Thomas Rösch, MD, have joined the GI Dynamics SAB. The GI Dynamics SAB was designed to advance the body of evidence and state of patient care through EndoBarrier utilization. The SAB will serve as a key resource to GI Dynamics during its Investigational Device Exemption clinical trial in the United States and will support ongoing clinical studies and commercialization in the United Kingdom, Germany, the Middle East and select European countries. “We are honored to have Dr. Holtmann and Dr. Rösch join the GI Dynamics SAB,” said Scott Schorer, president and chief executive officer of GI Dynamics. “Dr. Holtmann has developed a rich experience with EndoBarrier, and is currently the primary investigator of the ‘Effects and Mechanisms of Action of an Endoscopically Placed Duodenal-Jejunal Sleeve Device (EndoBarrier) in Obese Patients with Type 2 Diabetes: Focus on Intraluminal Triglyceride Digestion’ in Brisbane, Australia. Dr. Rösch has extensive gastroenterology and endoscopy experience; he conducted the first EndoBarrier procedures in Germany, and is leading the refinement of understanding mechanisms of action and the improvement of gastroenterological treatment protocols.” Dr. Holtmann is associate dean clinical at The University of Queensland and director of gastroenterology and hepatology at the Princess Alexandra Hospital in Brisbane. He also serves as director on boards of the West Moreton Hospital and Health Service and the Gallipoli Foundation.In addition to Dr. Holtmann’s training in medicine and gastroenterology, he completed a Master of Business Administration degree at the University of South Australia and is certified by the German Board of Physicians in Medical Informatics and Biostatistics. He has published more than 300 articles and book chapters in leading journals including the New England Journal of Medicine, Lancet, Gut and Gastroenterology, and has garnered more than 16,000 citations.In May 2016, Dr. Holtmann presented a poster on ‘Endoscopic Treatment of Obesity with a Duodenal-Jejunal Bypass Sleeve: Does Impairment of Fat Absorption Explain Weight Loss?’ at Digestive Disease Week (DDW). He also presented a poster on ‘Improvements of Liver and Glycemic Parameters After Duodenal-Jejunal Bypass Sleeve (DJBS) Insertion’ at DDW. “With my current research focused on the role of gut microbiome and brain–gut interactions, I’m excited to contribute to the GI Dynamics SAB,” said Dr. Holtmann. “Understanding the role of EndoBarrier should produce interesting research that will hopefully help patients.” Dr. Rösch is director of the Department of Interdisciplinary Endoscopy at the University Hospital Eppendorf in Hamburg, Germany. He previously was the chief of endoscopy and professor of diagnostic and therapeutic endoscopy at Charité Berlin, Campus Virchow Hospital from 2004 to 2008.Dr. Rösch has performed experimental studies on the topic of the secretion of pancreatic enzymes and has conducted scientific activity with endoscopy and endosonography in gastrointestinal diagnostics. His gastrointestinal research has been featured in over 230 publications, numerous review articles and more than 1,500 lectures. Dr. Rösch is also the editor of two endoscopic ultrasonography books and was editor in chief of the Endoscopy journal from 2004 to 2013, as well as deputy editor of endoscopy for the Gut journal. He is a board member of the German Society of Gastroenterology (DGVS) and of the DGVS Endoscopic Section. Dr. Rösch’s most recent study, ‘Performance Measures for Lower Gastrointestinal Endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative,’ is a multi-center approach by the ESGE and United European Gastroenterology. The study presented a list of key performance measures for lower gastrointestinal endoscopy to be adopted by pan-European endoscopy services.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Risk of heart transplant rejection reduced by desensitising patient antibodies

Posted by fidest press agency su martedì, 2 Maggio 2017

antibioticiParis, France. The risk of heart transplant rejection can be reduced by desensitising patient antibodies, according to research presented today at Heart Failure 2017 and the 4th World Congress on Acute Heart Failure. The breakthrough comes on the 50th anniversary of heart transplantation.Before heart transplantation the serum of heart transplant candidates is tested for levels of anti-human leukocyte antigen (HLA) which could bind to donor HLA antigens and cause rejection of the organ. At the time of transplantation, a virtual crossmatch is conducted to determine if the patient’s anti-HLA antibodies are directed against the donor’s specific HLA antigen – if yes, they are called “donor specific anti-HLA antibody” (DSA).
“Most centres do not perform heart transplantation in patients with a high DSA level since the risk of antibody-mediated rejection is high, particularly hyper-acute rejection,” said lead author Dr Guillaume Coutance, a cardiologist at Pitié-Salpêtrière Hospital in Paris, France. “Patients then have to wait for a donor with different HLA antigens.”To reduce the chance of rejection in these patients at high immunological risk, in 2009 Pitié-Salpêtrière Hospital began a desensitisation programme. The current study analysed the impact of the programme on survival after heart transplantations performed during 2009 to 2015.The type of desensitisation patients receive depends on their DSA level, which is measured by mean fluorescence intensity (MFI). An MFI between 500 and 1000 is considered “low DSA” and an MFI above 1000 is considered “high DSA”. All patients receive anti-thymocyte globulins and conventional immunosuppressive therapy (calcineurin inhibitors, mycophenolate mofetil, and corticosteroids).On top of this, patients with low DSA levels receive intravenous immunoglobulins. Patients with high DSA levels are treated with plasmapheresis before and after transplantation, followed by intravenous immunoglobulins after the complete cycle of plasmapheresis.The study included 523 patients who were 50 years old on average and 77% were men. Nearly half (46%) of patients had no DSA, 17% had low DSA, and 37% had high DSA levels. Patients were followed-up for an average of 3.7 years and survival was compared between the three groups.Compared to patients with no or low DSA, those with high DSA were more often younger, female, and had a ventricular assist device. The length of survival after transplantation was similar between the three groups, even after adjustment for age, sex, and having a ventricular assist device before transplantation. Survival at one year and at the end of follow-up was 79% and 73% for those with no DSA, 80% and 72% in patients with low DSA, and 84% and 76% in patients with high DSA levels, respectively (p=0.85). Antibody-mediated rejections were more common in patients with high DSA levels (27% versus 6% in patients with no DSA). These rejections occurred early (a median of 28 days after transplantation) in patients with high DSA levels but they had no impact on survival and could be treated. Patients with high DSA levels had more bleeding complications due to perioperative plasmapheresis. Dr Coutance said: “By desensitising patient’s antibodies, those with high immunological risk experience similar survival to patients without DSA. Pre- and post-operative plasmapheresis results in a dramatic drop in DSA levels, which reduces the risk of hyper-acute rejections and early antibody-mediated rejections. Intravenous immunoglobulins will neutralise DSA for weeks.” “Despite this regimen, antibody-mediated rejections were frequent but they were not associated with poor outcomes,” added Dr Coutance. “Two factors might explain these good results: early diagnosis of rejection with repetitive routine biopsies, and aggressive treatment of rejections with plasmapheresis and intravenous immunoglobulins even in subclinical rejections. The increased bleeding risk is explained by the loss of coagulation factors during plasmapheresis which is important but does not seem to impact survival.” He concluded: “This desensitisation programme could shorten waiting times and increase access to transplantation for patients at high immunological risk. However, it will probably not increase the number of transplantations since donor shortage is the limiting factor.” Authors: ESC Press Office.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

Acute Cardiovascular Care 2016 will put a spotlight on managing high risk patients

Posted by fidest press agency su sabato, 17 settembre 2016

navigatore coronarieThe annual congress of the Acute Cardiovascular Care Association (ACCA), a registered branch of the European Society of Cardiology (ESC), is held 15 to 17 October at the Centro de Congressos de Lisboa in Lisbon, Portugal. The full scientific programme is available here. This year features state-of-the-art presentations by leading experts on “managing risk in acute cardiovascular care”, the congress theme.Professor Doron Zahger, Chairperson of the Scientific Programme, said: “All healthcare professionals working in acute cardiac care manage high risk patients in various situations such as acute heart failure, cardiac arrest, acute coronary syndromes, and high risk arrhythmias which can lead to sudden death.”Acute cardiovascular care is the specialty of cardiology dealing with acute problems in need of urgent care including heart attack, cardiac arrest, and acute heart failure, but also other conditions leading to acute cardiovascular problems such as pulmonary embolism or stroke.Original scientific research will be unveiled in a rich abstract programme covering the entire spectrum of acute cardiac care.
New studies will be presented on the hot topic of diagnosing myocardial infarction in the ambulance and emergency room. Professor Zahger said: “Prompt and accurate diagnosis is essential to ensure that patients receive the right treatment quickly, that the damage caused by heart attack is limited, and that the risk of heart failure is minimised. Accordingly, much research is ongoing in an effort to diagnose myocardial infarction earlier and more accurately.”Novel methods using shock wave therapy or medication for regenerating heart tissue that has suffered from restricted blood supply (ischaemia) will be revealed. The techniques may reduce infarct size, control inflammation, and improve heart function in patients with ischaemic heart disease.Inequalities in treatment of cancer patients who have a heart attack will be presented for the first time. The media will hear first-hand how care of these patients compares to those without cancer and the impact on in-hospital outcomes.
The use of an implantable cardioverter defibrillator (ICD) to prevent sudden death is explored in patients who had an out-of-hospital cardiac arrest that was caused by acute myocardial infarction. “This is a unique use for ICDs and journalists will hear whether or not it shows promise for the future,” said Professor Zahger.ESC Gold Medallist Professor Keith Fox will give a keynote lecture during the inaugural session entitled “Vulnerable plaques in vulnerable patients”, providing journalists with new insights in this exciting field.An innovative virtual case area will showcase interactive demonstrations on a digital patient simulator. Cases with symptoms including palpitations, breathing difficulties, and swollen legs will be enacted in virtual patients created for the congress and discussed by international experts.This is the prime scientific event for all healthcare professionals working in acute cardiac care. More than 1000 delegates from around 80 countries are expected, including cardiologists, emergency physicians, intensive care physicians, interventionists, anaesthesiologists, imaging specialists, internists, cardiac surgeons, nurses, paramedics and other allied professionals who care for acutely ill cardiac patients. With hundreds of abstracts and more than 50 scientific sessions over three days, this is the event of the year in acute cardiovascular care.

Posted in Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

First European standards for management of heart attack patients

Posted by fidest press agency su mercoledì, 31 agosto 2016

cardiology congress-2016Rome, Italy The first European standards for the management of heart attack patients are launched today by the European Society of Cardiology-Acute Cardiac Care Association (ESC-ACCA). The quality indicators for acute myocardial infarction (AMI) are published in European Heart Journal: Acute Cardiovascular Care, ACCA’s official journal, and presented at ESC Congress together with the results of the inaugural implementation.1,2“Evaluating quality of care is part of modern healthcare but measuring it is difficult and does not solely rely on patient outcomes,” said first author Professor François Schiele. “For this reason it has become common practice to use quality indicators (QIs).”The first QIs in Europe for assessing the quality of care provided to patients admitted for AMI were developed by the ACCA, a registered branch of the ESC.The 20 QIs are in seven domains which cover the entire patient pathway: centre organisation, reperfusion-invasive strategy, in-hospital risk assessment, antithrombotic treatment during hospitalisation, discharge treatments, patient satisfaction, and composite QIs (CQIs) and mortality. There are 12 main and eight secondary QIs.Professor Schiele said: “The QIs are in line with current ESC guidelines3,4 and were designed with the goal of improving the quality of care for AMI patients across Europe. A second aim is to use them to evaluate how well centres are currently performing and which domains could be improved.”The QIs were implemented for the first time in two French nationwide registries of AMI patients admitted to a coronary or intensive care unit within 48 congress cardiologyhours of symptom onset. The analysis included 7839 patients, of whom 3670 participated in FAST-MI 2005 and 4169 participated in FAST-MI 2010.5For each patient, data was identified that would enable the calculation of the 20 QIs. The researchers also investigated the association between the QIs and three-year mortality. Overall, 12 QIs could be calculated from existing data in FAST-MI 2005 and 14 in FAST-MI 2010. Professor Schiele said: “None of the QIs we calculated showed performance above 90%, which means there is room for improvement in all domains.”The opportunity-based CQI was calculated by dividing the number of times particular care processes were performed by the number of opportunities to provide them. The average score was 52% in 2005 and 72% in 2010. Professor Schiele said: “This suggests that only half of the appropriate care processes were provided to patients admitted with a heart attack in 2005, which rose to 72% in 2010.”Performance on the opportunity-based CQI was divided into quartiles: 0%, 0–40%, 40–80%, and above 80%. The investigators found a decrease in mortality with increasing quartiles of the CQI. Compared to those with a score of 0%, patients with a score between 0 and 40%, 40% to 80%, or above 80% had a 17%, 27%, and 32% lower risk of death, respectively.6Centres with more than 20 patients in the study were benchmarked by comparing their opportunity-based CQI score to the national average in 2005 or 2010. Centres were classified as “low” (below national average), “intermediate” (not significantly different) or “high” quality (above). Twelve centres achieved “high” in 2005 and 22 in 2010, while 16 were classified “low” in 2005 and 17 in 2010.Professor Schiele said: “The opportunity-based CQI was related to survival, which provides further justification for assessing quality of care. The CQI also made it possible to classify centres as having high, average or low quality of care.”

Posted in Medicina/Medicine/Health/Science, Roma/about Rome | Contrassegnato da tag: , | Leave a Comment »

Patients and doctors urge to put EU air quality policy back on the agenda

Posted by fidest press agency su giovedì, 18 dicembre 2014

BruxellesBrussels.The European Commission presented yesterday at the European Parliament plenary in Strasbourg, its 2015 working plan. The new plan withdraws the proposal for the revision of the National Emission Ceilings Directive, a key EU legislative file aimed at regulating air quality by setting maximum emission levels for six main pollutants – PM, SO2, NOx, VOCs, ammonia and methane- that directly affect our health and the environment we live in.European Commission Vice-President Mr. Frans Timmermans announced that the Commission “will bring forward a modified proposal”, but he did not specify its exact timing.Timmermans announcement has dismayed and confused institutions and civil society representatives. Member of the European Parliament Sirpa Pietikäinen (Finland, EPP) reacted: “EU is lagging badly behind from the World Health Organisation recommendations (2) for good air quality. Hundreds of thousands of premature deaths still occur in Europe due to fine particles in the air. It is by no means smart regulation to delay new legislation to improve air quality.”
EFA President Breda Flood declared: “We are shocked at the death sentence imposed by the Commission on EU air quality policies. Air pollution has no boundaries and needs to be regulated at EU level. At this very moment, 9 out of 10 Europeans living in cities are breathing air that is harmful to their health. The majority of EU citizens consider air quality a major concern and expect political action to improve the air we breathe. (3) (4) The Clean Air Package is a paramount piece of legislation to improve this reality, a political tool that could save thousands of lives and protect people living with allergy, asthma and chronic obstructive pulmonary disease (COPD). In November, we urged to keep this legislation on the table (4) as we consider that improving current clean air policy now is imperative to ensure that our health will not be compromised in the future. Sustainable economic growth should protect people’s health. Therefore, we encourage the Members of the European Parliament to use their influence to put back on the political agenda air quality legislation for the next year”.EAACI President Nikos Papadopoulos declared: “The decision of the Commission to drop the revision of the National Emission Ceilings Directive is of profound concern, certainly to the medical community, but also to all Europeans. Almost 150 million EU citizens suffer from chronic allergic diseases, of which 70 million of asthma. The Commission move to stop further discussions on this key legislative proposal, equals denying the many allergy and asthma sufferers the perspective of an improved health future.
This approach disregards the huge societal benefits that sound environmental and public health policies are able to deliver to the European citizens. Health is a wealth, and the Commission cannot put short-term economic growth at the expense of people’s health. Only sustainable politics that take health, the major human need, into account, can guarantee a sustainable Europe”.

Posted in Cronaca/News, Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

ResearchMoz: Telemedicine Monitoring Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018

Posted by fidest press agency su venerdì, 4 Maggio 2012

Albany, New York, (PRNewswire) New Report Added in ResearchMoz Reports Database Telemedicine Monitoring Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018 The 2012 study has 590 pages, 206 tables and figures. Worldwide markets are poised to achieve significant growth as the telemedicine systems provide a way to improve clinical care delivery to patients with chronic disease, decreasing hospitalizations and visits to the emergency room. To Browse Full TOC, Tables & Figures visit: Chronic disease conditions are best treated early on when there is a change in patient condition and an early intervention can make a difference. It is even better to treat them in a wellness treatment environment before there are indications of chronic disease, before symptoms develop, by addressing lifestyle issues early on. Left to their own judgments, some patients typically are apt to make terrible decisions relating to their personal health either because of ignorance, genetic inheritance, or because of lifestyle habit. The ability to accurately access patient condition via a combination of advanced testing and telemonitoring creates the opportunity to intervene when what is called for clinically can make a difference, and permits provision for education regarding healthy living in a way that is likely to create compliance with clinician recommendations. Home telemonitoring programs need to use advanced technology. Effective monitors support patient education. They support timely clinician intervention based on real vital signs data gathered on a daily basis. Health care for patients with congestive heart failure has been shown to be successful in reducing hospitalizations and trips to the emergency department, making these critical measures unnecessary in many cases.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Ramsay Health Care to Replace PIP Implants at no Charge

Posted by fidest press agency su domenica, 8 gennaio 2012

London Ramsay Health Care has a small number of patients (around 150) with PIP implants. Ramsay will look after these patients. Where patients are concerned they should contact their surgeon or hospital. Specialist opinion, examination and scans will be at no charge for these patients. If there is a rupture or a clinical need PIP implants will be removed and replaced free of charge. Ramsay Health Care is the leading independent provider of acute hospital services to the NHS Ramsay Healthcare UK employs over 3,500 staff in the UK. Ramsay Health Care UK manages a portfolio of 40 sites including 22 acute care hospitals and 10 Treatment Centres managed on behalf of the NHS. Ramsay Health Care UK also manages three specialist neurological rehabilitation homes caring for patients with acquired or traumatic brain injury, stroke and other complex neurological conditions. Ramsay Health Care was established in 1964 and has grown to become a global hospital group with hospitals and day surgery facilities in Australia, United Kingdom, France and the Far East. The Group manages 117 hospitals and day surgery units, treats over 850,000 patients per annum and provides 9,300 patient beds.
Ramsay Health Care is now the largest operator of independent sector hospitals in Australia, providing services on behalf of the Australian Public Hospital System (NHS equivalent).

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

On assisted death

Posted by fidest press agency su martedì, 17 Maggio 2011

The Community of Protestant Churches in Europe, CPCE, publishes “A time to live and a time to die”, an aid to orientation on questions at the end of life, and the parallel internet page The 104 page brochure discusses fundamental questions of dying in the social, clinical and juridical context. It asks from theological and ethical perspective: What is human life? Where does our moral responsibility lie? How sensitive are we to the wishes of the patient? Here the aid to orientation takes up such central questions of medical ethics as the termination of life-extending measures, palliative care, assisted dying and suicide assistance. The CPCE churches support the protection of the human rights of the dying and terminally ill. These include the right to life up to the end and the right to refuse treatment. At the same time the churches oppose setting the principle of autonomy against solidarity, empathy and care for the sick and dying. The CPCE churches oppose a theological ethical justification for assisted dying and assistance for suicide. At the same time they realize the change in social attitudes to particular forms of assisted death and assisted suicide. The study emphasizes the necessity to improve the accompanying social, medical and caring conditions for a worthy life and dying. These include the extension and development of hospices and the advancement of palliative care in theory and practice. Church action is oriented towards care for human beings. The aid to orientation calls us to seek the protection of life and to work for worthy conditions of living and dying in clinics and hospices. As a further aid to orientation CPCE is also publishing today the internet site There, alongside the publication itself, texts from various lands and contexts introduce the theme. Website visitors are invited to comment and to join actively in the discussion.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Gastroparesi, dolore addominale sintomo frequente

Posted by fidest press agency su martedì, 1 giugno 2010

Nei pazienti colpiti da gastroparesi (Gp) il dolore addominale (Da) rappresenta un sintomo frequente, comparabile per frequenza alla nausea e al vomito, più comunemente riconosciuti, e la sua presenza risulta in correlazione con la qualità di vita ma non con lo svuotamento gastrico. Dinu Cherian e collaboratori, della Temple university school of medicine di Philadelphia, sono giunti a questa conclusione dopo aver sottoposto un gruppo di pazienti con presunta Gp a una scintigrafia di svuotamento gastrico e a un esame endoscopico del tratto gastrointestinale prossimale e dopo aver terminato la compilazione di una serie di questionari per valutare i sintomi (Pagi-Sym, patient assessments of gastrointestinal symptoms), il Da (modello abbreviato di McGill) e la qualità di vita. Tra i 68 pazienti con svuotamento gastrico ritardato, dei quali 58 erano donne, il Da era presente nel 90% dei casi e la nausea nel 96%. Il sintomo algico ha mostrato una localizzazione epigastrica nel 43% dei casi e ombelicale nel 13%, si è presentato quotidianamente nel 43% dei pazienti ed era costante nel 38%, inoltre era spesso scatenato dal consumo di cibo (72%) e lamentato durante le ore notturne (74%) fino al punto da interferire con il sonno (66%). Per quanto riguarda la gravità dei sintomi, valutata attraverso il Pagi-Sym, sono stati presi in considerazione il senso di pienezza addominale (3,8 +/- 0,2), il gonfiore (3,6 +/- 0,2), la nausea (3,6 +/- 0,2), il discomfort (3,3 +/- 0,2) e il dolore (3,0 +/- 0,2) ai quadranti superiori dell’addome, e il vomito (2,2 +/- 0,2). La gravità del Da, infine, non è apparsa correlata con lo svuotamento gastrico, ma si è riscontrato un rapporto di grado moderato con la qualità di vita. (fonte doctor news)

Posted in Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »